Moneycontrol PRO
you are here: HomeNewsBusiness

Zydus Cadila gets USFDA nod for orthostatic hypotension drug

The drug is used for certain patients who have symptoms of low blood pressure when standing. This condition is also known as orthostatic hypotension.

September 25, 2020 / 05:56 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Zydus Cadila has received final approval from the US health regulator to market Midodrine Hydrochloride tablets, used to treat orthostatic hypotension.

The drug is used for certain patients who have symptoms of low blood pressure when standing. This condition is also known as orthostatic hypotension.

Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Midodrine Hydrochloride tablets in the strengths of 2.5 mg, 5 mg, and 10 mg,Cadila Healthcare said in a regulatory filing.

Zydus Cadila is a part of Cadila Healthcare group. Zydus Cadila is a part of Cadila Healthcare group. The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

Ideas for Profit | What makes Cadila Healthcare a formidable player in COVID times?

Close

The group now has 298 approvals and has so far filed over 390 Abbreviated New Drug Application (ANDAs) since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs384.60apiece on BSE, 0.69 percent higher against their previous close.
PTI
first published: Sep 3, 2020 12:32 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark